Phathom Pharmaceuticals, Inc. PHAT R2KR3KPHARMA
Company Overview
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Why Investors Should Care
Generates a return on equity of 50.5%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $175.11M (+216.9% YoY); net profit $-221.25M.
- Trailing 12 Months Year-on-year growth — revenue +88.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 88.00% |
Stock Price Performance
| 1 Year: | -9.35% |
| 6 Months: | -10.97% |
| 3 Months: | -6.22% |
| 1 Month: | +13.23% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)51.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 50.5%.
CONS
- Trading 47.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PHAT Phathom Pharmaceuticals, Inc. R2KR3KPHARMA | 9.50 | -7.60 | $768.56M | 0.00% | -125.87% | 50.49% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.91M | 7.32M | 16.35M | 28.52M | 39.50M | 49.50M | 58.30M | 74.27M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 1.49M | 5.95M | 14.00M | 24.80M | 34.47M | 43.31M | 46.30M | 59.18M |
| Operating Income | -251.00K | -255.00K | -268.00K | -451.00K | -1.23M | -83.01M | -6.28M | -15.69M | -20.38M | -20.02M | -32.83M | -52.44M | -33.58M | -35.32M | -33.14M | -37.91M | -45.36M | -42.53M | -30.08M | -31.70M | -35.66M | -69.95M | -77.30M | -70.80M | -78.86M | -59.92M | -15.27M | -15.48M | -3.96M |
| Net Income | -254.00K | -260.00K | -290.00K | -484.00K | -1.25M | -87.76M | -68.11M | -98.01M | -20.14M | -21.10M | -34.10M | -53.72M | -34.84M | -36.55M | -36.66M | -40.66M | -50.92M | -51.09M | -37.81M | -40.97M | -43.24M | -82.85M | -91.45M | -85.58M | -94.32M | -75.81M | -29.97M | -30.37M | -17.58M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.00 | -0.98 | -1.07 | -1.33 | -1.32 | -0.89 | -0.84 | -0.76 | -1.42 | -1.56 | -1.32 | -1.31 | -1.05 | -0.41 | -0.37 | -0.21 |
| R&D Expense | - | - | 6.00K | 14.00K | 429.00K | 2.77M | 4.47M | 12.70M | 15.87M | 14.86M | 25.77M | 41.65M | 20.58M | 21.60M | 16.61M | 17.66M | 18.82M | 19.02M | 11.48M | 12.76M | 12.26M | 9.43M | 7.38M | 8.69M | 9.18M | 9.08M | 7.03M | 7.77M | 7.81M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 682.00K | 55.25M | 175.11M |
| Gross Profit | - | - | - | - | 0 | 515.00K | 47.28M | 152.51M |
| Operating Income | -1.23M | -106.22M | -125.67M | -135.08M | -172.44M | -167.31M | -277.47M | -159.99M |
| Net Income | -1.29M | -255.13M | -129.07M | -143.88M | -197.72M | -201.59M | -334.33M | -221.25M |
| Diluted EPS | - | - | - | -3.89 | -5.05 | -3.93 | -5.29 | -3.03 |
| R&D Expense | 20.00K | 20.37M | 98.15M | 72.34M | 71.44M | 49.90M | 34.08M | 32.78M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 902.00K | 257.18M | 295.11M | 189.43M | 164.81M | 413.84M | 378.32M | 259.15M |
| Total Equity | 0 | -1.29M | 227.96M | 194.27M | 72.16M | -74.81M | -72.76M | -253.58M | -438.17M |
| Cash & Equivalents | - | 879.00K | 243.76M | 287.50M | 183.26M | 155.38M | 381.39M | 297.26M | 129.97M |
| Long Term Debt | - | - | 22.78M | 39.63M | 89.67M | 95.26M | 137.84M | 201.41M | 209.09M |
| Total Liabilities | - | 2.19M | 29.22M | 100.84M | 117.28M | 239.62M | 486.60M | 631.90M | 697.32M |
| Current Liabilities | - | 2.19M | 3.75M | 55.52M | 18.92M | 26.24M | 38.78M | 85.73M | 132.04M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.02M | -36.51M | -69.69M | -148.46M | -146.53M | -137.58M | -266.77M | -166.78M |
| Investing Cash Flow | - | -25.25M | -1.04M | -328.00K | -1.04M | -1.63M | -135.00K | -229.00K |
| Financing Cash Flow | 1.90M | 304.65M | 114.46M | 44.71M | 120.04M | 367.58M | 182.77M | -288.00K |
| Capital Expenditure | - | -132.00K | -1.04M | -328.00K | -1.04M | -1.63M | -135.00K | -229.00K |
| Free Cash Flow | - | -36.64M | -70.73M | -148.78M | -147.57M | -139.21M | -266.90M | -167.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | 75.5% | 85.6% | 87.1% |
| Operating Margin % | - | - | - | - | - | -24,532.6% | -502.2% | -91.4% |
| Net Margin % | - | - | - | - | - | -29,558.9% | -605.1% | -126.3% |
| ROE % | 100.2% | -111.9% | -66.4% | -199.4% | 264.3% | 277.1% | 131.8% | 50.5% |
| ROCE % | 95.3% | -41.9% | -52.5% | -79.2% | -124.4% | -44.6% | -94.8% | -125.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Frazier Life Sciences Management, L.P. | 15.41% | 12.47M | $114.44M |
| 2 | Medicxi Ventures Management (Jersey) Ltd | 9.23% | 7.46M | $68.52M |
| 3 | Blackrock Inc. | 5.59% | 4.53M | $41.54M |
| 4 | Invesco Ltd. | 4.98% | 4.03M | $36.99M |
| 5 | Carlyle Group Inc. | 4.32% | 3.50M | $32.10M |
| 6 | Millennium Management Llc | 4.17% | 3.38M | $30.99M |
| 7 | Vanguard Capital Management LLC | 3.28% | 2.66M | $24.39M |
| 8 | GW&K Investment Management, LLC | 2.68% | 2.17M | $19.89M |
| 9 | Franklin Resources, Inc. | 2.44% | 1.97M | $18.09M |
| 10 | NEA Management Company, LLC | 2.42% | 1.96M | $17.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PHAT
Phathom Pharmaceuticals (PHAT) Stock Sees Modest Fair Value Cut After Analyst Target Cuts - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPdmR3eGtueF9LVGhLS2diNTJKX0g2V0FKZlJiYlJGbWdEcFhhdHlHQ09EZUw5Y0Nwb0dITl9yMmlQcUd2c01HRk43TkVJVkJhejlNaFJ4cVpITkdGZU5ReVNySUs5cGFHdzQ3b1FRQ3R0Ni1SNmFsZ3RkX25GMTlKU2t2UVJxV2IzZk5VVG…
PHAT Stock Clocks Worst Day In Over 1.5 Years — What Sparked The Selloff? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPeGVVMkZOdUE4NDZMLU1YWlN3QTNQTWZSN1ZULTdONXQzaXpzbXhrY2RiSXpUZm9EV29FRDVKaXpIcUdvSEh5WEFSZzAxUkdYektZcGNLLUZ2SE5IZC10ZHNIcUoxeHBpV19kVzdmMEw4M3JzNjVkeTRYejcycjFKZmtBc2JsdFpZNVp1dl…
Phathom Pharmaceuticals (PHAT) Stock Slides Despite Cash Profit Breakthrough - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi7gFBVV95cUxPX1d6cXZ0U3FBdjg4a2ZaQWUtVUc3WldVOUZ1VzZEdllvRzhqcmhuTklHN2JIRGpvZmFjaEZVeXRkSC1RVmxzS2VDNWtNYVNZWVRzSW5RN2NsVmhXVzdMUGZiRG9JdDdPTkN4Yk9Tc04yZjdoUlZ2UGdwRFdXbkh3OGlPTjF1SktxMGdWUn…
PHAT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Phathom Pharmaceuticals - Morningstar
<a href="https://news.google.com/rss/articles/CBMikwJBVV95cUxQWTRtOUVvSnFqU3NlOEFlck8xSUl6WUlqNXkzbHlUMlBkdzlLRHlwUHB6YUpMRVdsOTBicDlSWFo5MW1uVTlsRzdQdlR6WXU1X3RJUWFFZkFRNEZyeGtueFZVUmZiRlFEWG94MlVYaUkxZWYxQVRHX0p4dWZYM1JJcXhEVXQ5dzQ4WFpLLT…
Price-Driven Insight from (PHAT) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxPSzFkMl9nR3VrWlBVTTJ0ZWNydldBT25LVHRXZjFhdkRMQUJBTEJjZURyemp3eG9MWVlZTi1oZlI2WlAxVlRWV2hPMmtVZ1ZOdGw0OTBna3RGWmY4UWRoVmI2VjBLWGZqUU1WelBZdXJocmtqdGlpVzBiLU4wNWhMaDJCcHRWbzF3N25VU2…
Phathom Pharmaceuticals Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Phathom Pharmaceuticals (PHAT) - PR Newswire
<a href="https://news.google.com/rss/articles/CBMinwJBVV95cUxQTFQ3LWE3UjBrM1VnYXp5VXVfb0c5S0ltNjVsQjVPeW9oUkRTNmZEdHBDWTJhdTdEc1BxaDBUZ2FwcC1ZbmtiTnA5bFdJblhTT24zRFRlRlJCZjk4eUNHdl80R0JCN1lkTFdCUUl3SnRVQWRyLVlXUWI0ck5lRXFnSU1MTnd2VXEzempsdj…
PHAT — Frequently Asked Questions
What is the current share price of Phathom Pharmaceuticals, Inc. (PHAT)?
As of 2026-09-07 16:24 PDT, Phathom Pharmaceuticals, Inc. (PHAT) trades at $9.50 on NasdaqGS. Its 52-week range is $8.23 to $18.08.
What is the market capitalisation of PHAT?
Phathom Pharmaceuticals, Inc. (PHAT) has a market capitalisation of $768.56M on NasdaqGS.
What is the P/E ratio of PHAT?
PHAT trades at a trailing price-to-earnings (P/E) ratio of -7.60. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -1.99.
What is the return on equity (ROE) of PHAT?
PHAT has a return on equity (ROE) of 50.49%. Its return on capital employed (ROCE) is -125.87%.
Is PHAT a good stock to buy?
This page provides a data-driven analysis of Phathom Pharmaceuticals, Inc. (PHAT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.